Evidence map›Paper›PMID 33765517›Full record

ArticleThe International journal on drug policy2021

"I wanted to close the chapter completely … and I feel like that [carrying naloxone] would keep it open a little bit": Refusal to carry naloxone among newly-abstinent opioid users and 12-step identity.

J M Bowles, L R Smith, M L Mittal, R W Harding, E Copulsky, G Hennessy, A Dunkle, P J Davidson, K D Wagner

Open access · greenAbstract read
In one paragraph

Article in The International journal on drug policy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

J M BowlesUniversity of California San Diego, Division of Infectious Diseases and Global Public Health, La Jolla, CA, United States; Centre on Drug Policy Evaluation, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, ON, Canada.
L R SmithUniversity of California San Diego, Division of Infectious Diseases and Global Public Health, La Jolla, CA, United States.
M L MittalUniversity of California San Diego, Division of Infectious Diseases and Global Public Health, La Jolla, CA, United States.
R W HardingSchool of Community Health Sciences, University of Nevada, Reno, United States.
E CopulskyUniversity of California San Diego, Division of Infectious Diseases and Global Public Health, La Jolla, CA, United States.
G HennessyUniversity of California San Diego, Division of Infectious Diseases and Global Public Health, La Jolla, CA, United States.
A DunkleSolace Foundation, CA, United States.
P J DavidsonUniversity of California San Diego, Division of Infectious Diseases and Global Public Health, La Jolla, CA, United States. Electronic address: pdavidson@health.ucsd.edu.
K D WagnerSchool of Community Health Sciences, University of Nevada, Reno, United States. Electronic address: karlawagner@unr.edu.
University of California, San Diego · USUniversity of Nevada, Reno · US

Funding

Training Program in Substance Use, HIV and Related InfectionsT32DA023356 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Natasha Martin, Steffanie A Strathdee · 2007 to 2026
$7.8M
Impacts of a Novel law-enforcement delivered intervention on drug user healthR01DA040648 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DAVIDSON, PETER JOHN · 2016 to 2021
$2.6M
HIV Treatment and Substance Use in LMIC Shaping MSMs Sociostructural ContextK01DA039767 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SMITH, LARAMIE RAE · 2015 to 2019
$906k
NCIPC CDC HHS U01 CE002778NIDA NIH HHS K01 DA039767NIDA NIH HHS R01 DA040648NIDA NIH HHS T32 DA023356
6 · The paper itself

Abstract

background12-step programs aim to address drug-related harms, like opioid overdose, via abstinence. However, abstaining from opioids can diminish tolerance, which increases risk for overdose death upon resumption. A recent study found that desire to abstain from drugs inhibited willingness to participate in take-home naloxone programming, which was linked to perceptions of harm reduction strategies being tied to drug use. In the present study, we uncovered a similar phenomenon occurring among newly-abstinent participants who were refusing to carry naloxone.

methodsThis study is an analysis of broader qualitative data collected throughout Southern California among persons who use opioids, including those recently abstinent. Preliminary analysis revealed that those newly abstinent refused to accept naloxone at the end of interviews, and so we began probing about this (N=44). We used thematic analysis and author positionality to explicate the emergent phenomenon and applied social identity theory to conceptualize findings.

resultsMechanisms underlying naloxone refusal included its tie to a drug-using identity that newly-abstinent participants were attempting to retire. Carrying naloxone was also viewed as pointless due to doubt of witnessing an overdose again. Furthermore, the thought of being equipped with naloxone was not believed to be congruent with an abstinent identity, e.g. "me carrying it [naloxone] is making me feel like I'm going to be hanging out with people that are doing it [using drugs]."

conclusionRecent detoxification heightens vulnerability to overdose, which other newly-abstinent peers might be positioned to respond to as bonds are formed through 12-step identity formation. However, naloxone is often refused by this group due to perceived 12-step identity clash. While some treatment spaces distribute naloxone, 12-step identity associated behavioral expectations appear to conflict with this strategy. Reframing these disconnects is essential for expanding the lifesaving naloxone community safety net.

Indexed as

Drug OverdoseOpioid-Related DisordersAnalgesics, OpioidHumansNaloxoneNarcotic AntagonistsAnalgesics, OpioidNaloxoneNarcotic AntagonistsAbstinenceDrug treatmentHarm reductionOpioidsOverdoseQualitative methodsSocial identity theory

Identifiers

PMID33765517
PMCPMC10155624
OpenAlexW3136657178

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.